Remimazolam
From Wikipedia, the free encyclopedia
 | |
|---|---|
| Systematic (IUPAC) name | |
| methyl 3-[(4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate | |
| Clinical data | |
| Legal status | ? |
| Identifiers | |
| CAS number | 308242-62-8  |
| ATC code | ? |
| PubChem | CID 9824461 |
| UNII | 7V4A8U16MB |
| Chemical data | |
| Formula | C21H19BrN4O2 |
| Mol. mass | 439.304 |
| SMILES
| |
| (what is this?) (verify) | |
Remimazolam[1] (CNS-7056) is a drug which is a benzodiazepine derivative, developed as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures. Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trial results showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.[2][3]
See also
References
- ↑ EP Patent 1183243
- ↑ Rogers WK, McDowell TS (December 2010). "Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures". IDrugs : the Investigational Drugs Journal 13 (12): 929–37. PMID 21154153.
- ↑ Saari TI, Uusi-Oukari M, Ahonen J, Olkkola KT (March 2011). "Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology". Pharmacological Reviews 63 (1): 243–67. doi:10.1124/pr.110.002717. PMID 21245208.
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.